Cargando…

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice

Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Oswald, Jessica C, Schuster, Nathaniel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181111/
https://www.ncbi.nlm.nih.gov/pubmed/30323656
http://dx.doi.org/10.2147/JPR.S152216
_version_ 1783362344548564992
author Oswald, Jessica C
Schuster, Nathaniel M
author_facet Oswald, Jessica C
Schuster, Nathaniel M
author_sort Oswald, Jessica C
collection PubMed
description Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the vasoconstriction associated with triptans limit their use in patients with pre-existing cardiovascular risk factors. Preferential 5-HT(1F) agonists have shown promising results in in vitro and early proof-of-concept trials. Lasmiditan, a highly selective 5-HT(1F) agonist, has completed two Phase III randomized, double blind, placebo-controlled clinical trials, with a third – a long-term, open-label safety study – still underway. Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors.
format Online
Article
Text
id pubmed-6181111
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61811112018-10-15 Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice Oswald, Jessica C Schuster, Nathaniel M J Pain Res Review Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the vasoconstriction associated with triptans limit their use in patients with pre-existing cardiovascular risk factors. Preferential 5-HT(1F) agonists have shown promising results in in vitro and early proof-of-concept trials. Lasmiditan, a highly selective 5-HT(1F) agonist, has completed two Phase III randomized, double blind, placebo-controlled clinical trials, with a third – a long-term, open-label safety study – still underway. Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors. Dove Medical Press 2018-10-08 /pmc/articles/PMC6181111/ /pubmed/30323656 http://dx.doi.org/10.2147/JPR.S152216 Text en © 2018 Oswald and Schuster. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Oswald, Jessica C
Schuster, Nathaniel M
Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
title Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
title_full Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
title_fullStr Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
title_full_unstemmed Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
title_short Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
title_sort lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181111/
https://www.ncbi.nlm.nih.gov/pubmed/30323656
http://dx.doi.org/10.2147/JPR.S152216
work_keys_str_mv AT oswaldjessicac lasmiditanforthetreatmentofacutemigraineareviewandpotentialroleinclinicalpractice
AT schusternathanielm lasmiditanforthetreatmentofacutemigraineareviewandpotentialroleinclinicalpractice